BCAT1 and gastric adenocarcinoma: At the advanced stages (American Joint Committee on Cancer), BCAT1 demonstrated diverse expression levels in various cancers—increased levels in kidney renal papillary cell carcinoma, STAD, and testicular germ cell tumors; reduced levels in CHOL, lung adenocarcinoma, pancreatic adenocarcinoma (PAAD), SKCM, and THCA (Figure 5C), suggesting that BCAT1 may play different roles in these cancers.